Articles tagged with Alzheimer Disease
Researchers from Rush University Medical Center found that diseased blood vessels in the brain may contribute more significantly to Alzheimer's disease dementia than previously believed. The study analyzed medical and pathologic data on 1,143 older individuals and found an association between worsening brain vessel diseases and higher ...
Researchers developed an anti-apoE4 specific monoclonal antibody that reverses key brain-related pathological effects of apoE4 and associated cognitive deficits in mice. The treatment also accumulates in the brain and binds to apoE4, suggesting a novel approach for AD therapy.
Researchers found that THC and other cannabinoids reduce amyloid beta protein levels and eliminate inflammatory responses in brain cells. This study may provide insights into developing novel therapeutics for Alzheimer's disease.
Researchers propose a novel combination therapy using resveratrol, antioxidants and iron chelators to slow down Alzheimer's disease progression. The addition of resveratrol may enhance cell viability and longevity by activating AMPK and sirtuin pathways.
Researchers from University of Miami Miller School of Medicine's John P. Hussman Institute for Human Genomics are studying genetic factors contributing to Alzheimer's disease risk. The institute is expanding research to include African-American populations, a diverse and underrepresented group in Alzheimer's disease research.
Researchers found that blocking acetylcholine in genetically modified mice caused Alzheimer's-like pathology, highlighting the importance of this neurotransmitter for brain health. The study suggests that targeting one of the affected messenger RNA pathways may lead to a reversal of dementia progression.
Researchers aim to identify genetic risk and prevention factors for Alzheimer's disease by analyzing genomic sequence data from thousands of individuals. The new center will provide a common database for critical information sharing and interpretation, enabling progress against the insidious disease.
The Coordinating Center for Genetics and Genomics of Alzheimer's Disease will aggregate and analyze large data sets to identify genetic risk factors and potential therapeutic targets. This effort aims to accelerate progress in solving the devastating disease.
Research reveals a close relationship between Alzheimer's disease and type 2 diabetes, with drugs used to treat diabetes potentially alleviating Alzheimer's symptoms and vice versa. The study found that dementia-related complications can lead to changes in glucose handling and ultimately diabetes.
Research by Thomas Willnow found that SORLA regulates insulin signaling, leading to increased fat accumulation and obesity in mice. Reducing SORLA levels protected against diet-induced obesity.
Recent studies suggest that nicotinic acetylcholine receptors (nAChRs) in Alzheimer's disease are influenced by direct interactions with proteins such as Lynx, NMDA-receptors, and the Wnt/β-catenin pathway. This new understanding adds complexity to cholinergic signaling in the brain and may lead to the development of targeted drugs.
A groundbreaking study shows unprecedented improvements in 10 patients with early Alzheimer's disease or precursors following treatment with a personalized, 36-point therapeutic program. Patients who were struggling with memory loss returned to work and improved their performance after just 10 months on the protocol.
A novel PET imaging study reveals a significant correlation between increased tau and decreased metabolic activity in the brains of living Alzheimer's patients, indicating clear signs of neurodegeneration. The study measures amyloid plaques, tau tangles, and metabolic activity using three different radiotracers.
Researchers at the Babraham Institute have developed a technique to replicate early changes in Alzheimer's disease in a lab-dish model. This breakthrough allows for the study of the disease's progression and potential treatments without animal testing.
A team of researchers has developed a nanoprobe that enables the direct measurement of key proteins within living, cultured cells. The device tracked levels of Alzheimer's-disease-associated proteins amyloid-beta and tau in neurons exposed to an anesthetic, revealing that A-beta generation precedes tau phosphorylation.
A new PET study reveals that tau protein tangles in the brain may be driving the neurodegeneration behind Alzheimer's disease. The research found a significant correlation between increased tau and decreased metabolic activity in the brain, suggesting that tau imaging could be used to detect neuronal injury earlier than amyloid imaging.
Scientists at Hong Kong University of Science and Technology discover that interleukin-33 (IL-33) rescues contextual memory deficits and reduces beta-amyloid peptide deposition in AD mouse models, suggesting a new therapeutic intervention.
A dietary supplement containing 30 natural ingredients has shown promise in preventing and reversing massive brain cell loss in mice. The supplement was found to completely eliminate severe brain cell loss and abolish cognitive decline in mice with widespread brain damage.
Researchers at Indiana University have found a correlation between higher levels of an enzyme called NMNAT2 and better cognitive function in older people. This study suggests that NMNAT2 may help protect against neurodegenerative brain diseases, including Alzheimer's.
Researchers at RIKEN discovered that acrolein can combine with polyamines to form substances that prevent the aggregation of amyloid-beta peptides, a process linked to Alzheimer's disease. The findings suggest that acrolein may have an anti-fibrillation effect, potentially influencing the progression of neurological disorders.
Researchers suggest a long-term memory test combined with a brain scan can detect early Alzheimer's disease. Long-term memory tests reveal deficits in the brain's ability to remember, which may be reversed by new treatments.
Researchers found that treatment with an anti-platelet drug reduces amyloid plaques in cerebral vessels, improving brain perfusion. Alzheimer's disease is characterized by the formation of protein agglutination and deposits of amyloid in the brain, leading to progressive cognitive decline.
A new study published in Radiology found increased blood-brain barrier permeability in people with early Alzheimer's disease. The researchers used contrast-enhanced MRI to identify leakages in the BBB, which could represent a key mechanism in the early stages of the disease.
A study suggests that amyloid-ß peptide can ensnare invading microbes, halting infection in mouse and worm models of Alzheimer's disease. Researchers also found that mice with overexpressed amyloid-ß showed greater resistance to bacterial infection.
A new study finds that human amyloid-beta is protective against infections in mice and roundworms, and may lead to new treatments for Alzheimer's disease. The protein's oligomeric form appears to entrap microbes, providing a natural defense mechanism.
Recent advancements in neuroimaging technology have led to better understanding and treatment of neurodegenerative diseases such as Alzheimer's. These innovations enable clinicians to detect preclinical stages of AD through PET imaging, and also provide new therapeutic interventions.
Researchers have developed a new method for detecting and diagnosing preclinical Alzheimer's disease using PET imaging with PiB, which binds to amyloid plaques in the brain. The study found that PiB retention was prominent in cortical areas of the brain, consistent with post-mortem studies of Aβ plaques.
Researchers at Uppsala University found that men with Y chromosome loss in blood cells are at higher risk of developing Alzheimer's disease. The study, published in the American Journal of Human Genetics, suggests a potential simple test to identify those at risk.
Researchers found that men with blood cells lacking a Y chromosome are at increased risk of developing Alzheimer's disease. The study analyzed over 3,000 men and discovered that those with higher levels of lost Y chromosomes were more likely to be diagnosed with Alzheimer's.
Researchers found that current screening tools result in a 7% false-negative error rate, misclassifying individuals with mild cognitive impairment as cognitively normal. This can lead to delayed diagnosis and treatment, impacting individual health and research studies.
Research links loss of Y chromosome in blood cells to increased risk of developing Alzheimer's disease in men. A study of over 3,200 men found that those with an existing diagnosis of AD had a higher degree of lost Y chromosome, and LOY was also a marker for the likelihood of developing the disease.
Researchers propose Spherical Brain Mapping (SBM) to detect Alzheimer's disease, achieving 91% accuracy in differential diagnosis. The framework projects three-dimensional MR brain images onto two-dimensional maps, revealing statistical characteristics of tissue, and can be visually assessed for diagnosis.
A recent study published in NeuroImage found a positive correlation between fitness and increased blood flow to areas of the brain where Alzheimer's pathology is usually first detected. Regular physical activity, regardless of age, may provide some protection from dementia.
Researchers propose an out-of-control immune system as a common cause of neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's. The theory suggests that prolonged activation of the innate immune system leads to brain cell death, contributing to the decline in these diseases.
Researchers found that tau tangles are a better indicator of dementia in late-stage Alzheimer's disease, correlating with cognitive deficits and cerebrospinal fluid tau levels. PET imaging also showed stronger associations between tau deposits and amyloid plaques than previously thought.
Researchers at WashU Medicine have developed a new imaging agent that better predicts Alzheimer's disease progression than amyloid beta. The study found elevated tau levels are associated with cognitive decline and predict symptoms of dementia.
A €3.5 million pan-European consortium is developing Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer's Disease (BBDiag) to improve diagnosis and clinical trial success rates. The project aims to train a new generation of researchers and develop disease-modifying treatments and prevention strategies.
Researchers have identified genetic variations in the PKC alpha enzyme that boost its activity and contribute to the development of Alzheimer's disease. These variants were found in five families with late-onset Alzheimer's disease and are associated with increased PKC alpha activity.
Scientists have successfully enhanced reaction velocity constants for proteins turning into toxic substances by 1,000 times using ultrasonic irradiation. This breakthrough can be applied to early diagnosis and treatment of Alzheimer's disease.
A USF professor is investigating the possibility that CTE can start when an on-field collision generates a 'seed' that spreads protein abnormality in the brain. Similar processes may be at work for Alzheimer's and Parkinson's diseases.
Researchers found no association between cancer and a decreased risk for Alzheimer's disease, contrary to previous studies. Higher mortality rates among cancer patients suggest other factors contribute to the development of the neurodegenerative disorder.
A newly discovered pathway in Alzheimer's disease may provide new treatment approaches by targeting the formation of tau-stress granules. Reducing key stress granule proteins prevents tau aggregation and nerve cell degeneration.
Researchers found that riluzole reversed key genetic changes associated with Alzheimer's and cognitive decline in rats. The drug restored expression of glutamate-clearing molecules and genes critical for neural communication and plasticity.
A new study has found a link between rosacea and an increased risk of dementia, with the highest risks seen in older patients. The study published in Annals of Neurology suggests that treating rosacea may also modify patients' risk of developing dementia.
Researchers found that micro-needle insertion into the hippocampus of mice with Alzheimer's disease reduced beta-amyloid plaques and improved memory tasks. The procedure also triggered neurogenesis in the brain, suggesting a potential new approach to treating neuro-cognitive disorders.
Researchers identified a compound that reverses symptoms of Alzheimer's and Parkinson's diseases in genetically altered fruit flies. The study suggests that the treatment could work for humans by targeting a specific enzyme involved in disease progression.
A lab-based study led by University of Leicester researchers has found a way to 'reverse' symptoms of neurodegenerative diseases like Parkinson's and Alzheimer's using genetic and pharmacological approaches. The study utilized fruit flies to explore the role of specific metabolites in the kynurenine pathway, which can help alleviate sy...
The grant aims to study APP processing and its role in synaptic transmission, potentially shedding light on Alzheimer's pathogenesis and revealing treatment targets.
The Alzheimer's Association has awarded $4.3 million to accelerate the testing of new potential therapies and diagnostic approaches for Alzheimer's disease. The funding will support innovative trial designs, including tau PET imaging and home-based cognitive testing, to improve early detection and treatment options.
Researchers found that difficulties building cognitive maps of new surroundings could indicate Alzheimer's disease. Participants with preclinical Alzheimer's disease showed significant challenges forming cognitive maps but not route learning tasks, highlighting the hippocampus and caudate as early affected brain regions.
Researchers at McGill University find that the combination of amyloid and tau proteins causes brain damage in cognitively intact individuals, offering new insights into Alzheimer's disease progression. The study's findings suggest that therapeutic strategies targeting both proteins may be effective in preventing or stabilizing AD.
Researchers found lower metabolism and reduced brain size among study participants taking anticholinergic drugs, which may increase risk of cognitive impairment and dementia. The study provides insight into the potential underlying biology of these clinical links using neuroimaging measurements.
Memories formed in one part of the brain are replayed and transferred to another area for consolidation, according to a new UCL study. The process, essential for tackling Alzheimer's disease, involves the transfer of memories from the hippocampus to the entorhinal cortex.
Researchers investigate relationship between plasma Aβ levels, cognitive function, and brain volumetrics in Alzheimer's patients. Plasma Aβ measures may serve as biomarkers for early diagnosis of Alzheimer's disease.
A 71-year-old HIV-positive man was diagnosed with Alzheimer's disease through a PET scan showing amyloid deposition in the brain. This finding suggests that some older HIV-positive patients may be misdiagnosed with HIV-associated neurocognitive disorders and highlights the need for accurate diagnosis to guide treatment.
Researchers at the University of Bergen have found a link between a gene defect and Alzheimer's disease, identifying protein PITRM1 as a crucial factor in disease development. The study suggests that reduced levels of this protein may lead to increased amyloid deposition in the brain.
Researchers at Rush University Medical Center are conducting a five-year randomized trial to test the MIND diet's effects on cognitive decline and Alzheimer's disease incidence. The study will enroll 600 individuals aged 65+ and evaluate the diet's impact on brain structure, cognition, and health outcomes.
The Alzheimer's Association has developed recommendations for patient care milestones, including workforce development, timely diagnosis, education, and care guideline measures. Caregiver support strategies include culturally sensitive training, enabling caregivers to balance care with their own well-being, and addressing housing needs.
Research by Dr. Sven Joubert reveals that Alzheimer's disease affects holistic face perception, leading to difficulties in recognizing faces of family members or celebrities. This impairment is observed even in the early stages of the disease, highlighting potential strategies for patients to recognize their loved ones for longer.
Researchers have designed molecules that promote the formation and retention of memories by increasing dendritic spine density in neurons. The compounds also prevent the loss of these spines in the presence of amyloid-beta, a protein implicated in Alzheimer's disease.